Representatives from 22nd Century Group will ring the closing bell on Nasdaq on August 26, 2022 to celebrate the launch of VLN, a reduced nicotine tobacco product.
Image: Mat Szymański
In December 2021, the U.S. Food and Drug Administration authorized 22nd Century Group to sell VLN cigarettes as a reduced-risk tobacco product. VLN cigarettes are the first combustible cigarettes to receive this approval.
Since then, the company has launched its VLN cigarettes in various test markets, including the Chicago area. According to 22nd Century Group, the Chicago test exceeded expectations, prompting the company to accelerate the expansion of its market to Colorado.
John J stated, "Our VLN pilot program in Chicago has confirmed the market's interest in VLN, as adult smokers are seeking new tools to help them reduce smoking, which is an important step in improving overall public health." Miller, CEO of 22nd Century Tobacco, explained this in a statement.
Based on the better-than-expected results of our pilot program, we are accelerating our plans to expand our market and begin selling through multiple partnership channels in Colorado. These partners are committed to helping us provide a genuine tobacco harm reduction option for adult smokers.
Statement
This article is compiled from third-party information and is intended for industry communication and learning purposes only.
This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's contents. The translation of this article is only intended for industry exchange and research.
Due to limitations in the translation process, the translated article may not accurately reflect the original text. Please refer to the original article for accuracy.
In regards to any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions, 2FIRSTS maintains complete alignment with the Chinese government.
Information compiled is the intellectual property of the original media and its respective author. If there is any infringement, please contact us for removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
